Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
In this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion. (Funded by the Acerta Pharma and others; ClinicalTrials.gov number, NCT02029443.).